For Treatment of Rheumatoid Arthritis, Surveyed Rheumatologists and Patients Differ In Their Perception of Bristol-Myers Squibb's Orencia
WALTHAM, Mass., July 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that surveyed rheumatologists' perception of Bristol-Myers Squibb's Orencia
is low among rheumatoid arthrit...
Does the Crowded TNF Market Really Need Two New Agents? Rheumatologists Provide Insight in the Wave One Report of LaunchTrends(TM): SIMPONI and CIMZIA
...ade) which have been the target of Cimzia and Simponi's launches, the survey respondents anticipate that Actemra would be most likely to replace BMS's orencia
in their practices.
LaunchTrends (TM) measure launch effectiveness of new products from FDA approval through six months post launch. The next...
Global Autoimmune Disease Therapeutics Market to Reach $50 Billion by 2015, According to a New Report by Global Industry Analysts
...sent day treatment of autoimmune diseases include TNF inhibitors, such as Enbrel, Humira and Remicade. New products in the market, such as Rituxan and orencia
made significant inroads by addressing therapeutic needs not addressed by existing drugs.
The global marketplace is characterized by participants ...
Rheumatoid Arthritis Drug Might Fight Swine Flu
...ia, and the U.S. National Institutes of Health.
was approved for use in the United States in 2005 ...before the mice actually fell ill, half were given orencia
while the remaining half were left untreated.
In both sets of mice, those that had received orencia
cleared the virus quicker, got less sick and recov...
Growth Opportunities for Actemra Will Propel Roche to Sixth Position in the Rheumatoid Arthritis Market by 2012
... Japan until the arrival of Bristol-Myers Squibb's orencia
in 2012, and the likelihood that the drug will be ...ve agents with other mechanisms of action, such as orencia
and Biogen Idec/Genentech's Rituxan (also marketed...in promotional spend coinciding with the launch of orencia
and Rituxan, these relatively new entrants are str...
Drug May Ease Symptoms of Juvenile Arthritis
...th other treatments may benefit from a drug called orencia
The conclusions follow from a rand... assigned to receive 10 milligrams per kilogram of orencia
at 28-day intervals for six months or until the ar...patients on the placebo and 20 percent of those on orencia
experienced an exacerbation of their condition. Th...
Celebrity Chef Sandra Lee Offers Recipes and Shortcuts in the Kitchen to People with Rheumatoid Arthritis
...small dinner party with friends," continued Lee.
is a prescription medicine used to treat adults wi...tol-Myers Squibb.
About ORENCIA(R) (abatacept)
is a prescription medicine that is used to treat a... even though they may
have tried other treatments. orencia
can be used alone or with other
Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007
... 462 362 28 % 361 294 23 % 11 % Immunoscience orencia
75 32 134 % 66 31 113 % N/A Other Pharm... 1,660 1,282 29 % 1,305 1,052 24 % 12 % Immunoscience orencia
231 89 160 % 216 88 145 % N/A Other Phar...
Investigational Study Demonstrated a Re-Establishment of Clinical
Improvement with Orencia (Abatacept) in Children with Juvenile
Idiopathic Arthritis upon Re-Introduction of Therapy
BARCELONA, Spain, June 15, 2007 /PRNewswire-FirstCall/ --
Bristol-Myers Squibb Company today announced results regarding the
efficacy and safety of ORENCIA(R) (abatacept) from the open-label
phase of an ongoing investigational study in children with juvenile
idiopathic arthritis (JIA) who have had...
U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
... - orencia
is a First-in-Class Biologic Treatment Option Now ...therapy, such as anakinra. This new
indication for orencia
provides significant evidence of its durable
effic...three-part study through one year. The
approval of orencia
in JIA represents the ongoing commitment of
Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)
... n=219 for placebo plus MTX) and ATTAIN (n=258 for orencia
DMARDs; n=133 for placebo plus DMARDs) studie...tion questionnaire. Patients who were
treated with orencia
were compared with those in the placebo group. Thi...pate in
daily activities in AIM was 61 percent for orencia
vs. 46 percent for
placebo at one year, and in ATT...
Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
(MTX). The data show that, in these patients, orencia
improvements in ACR responses, ...ion rates observed in this
study, demonstrate that orencia
provides durable long-term clinical
benefits in pa...ontrolled
randomized trial received MTX and either orencia
(10 mg/kg or 2 mg/kg) or
placebo administered as a...
ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
...n which all participants (6-17 years old) received orencia
clinical response and safety were assesse...thdrawal phase in which responders received
or placebo and time to disease flare and safety we...en- label phase in which all participants
in order to assess long-term efficacy and safety (...